UNSPSC 51191504: Bumetanide

This classification denotes a loop diuretic with the molecular formula C17H20N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0Y2S3XUQ5H, chemically known as benzoic acid, 3-(butylamino)-4-phenoxy-5-sulfamoyl- but generally known as bumetanide, which bears US NIH Compound Identifier 2471. European Medicines Agency schedules Bumetanide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05971MIG.

UNSPSC 51191504 Bumetanide is a Commodity code nominally indexing a specific loop diuretic pharmaceutical, but recent state and local solicitation activity under this code shows a substantial mismatch between the code label and actual procurement scope. The City of Meriden (Connecticut) posted a chemical supply solicitation for sodium bisulfite used in water treatment operations, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. The pharmaceutical RFP addresses a wide range of generic drugs and OTC items through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with vendor submissions specifying National Drug Codes, strengths, dosage forms, and packaging configurations. These recent opportunities indicate that the code as currently applied captures both chemical commodity supply for municipal infrastructure and broader pharmaceutical procurement frameworks, suggesting either categorization drift or state and local systems tagging heterogeneous products under a single numeric identifier.

The geographic spread includes Minnesota and Oregon as MMCAP member jurisdictions, with Connecticut municipal procurement also active. MMCAP issued its RFP January 20, 2026 with proposals due March 26, 2026; awarded vendors were to be provided to wholesalers by May 15, 2026 with contract effectiveness July 1, 2026. The City of Meriden's sodium bisulfite solicitation (number B027-15) posted July 8, 2026 with bids due July 29, 2026, requiring General Liability coverage of $1,000,000 to $2,000,000, performance and labor/material payment bonds, and firm pricing for the contract term. The MMCAP pharmaceutical RFP emphasizes pricing competitiveness (weighted 75 percent), cGMP and Drug Supply Chain Security Act compliance, EDI capability, and pricing flexibility through flat price, net price, or WAC-minus structures, with a 3 percent administrative fee imposed on all contract purchases. The code shows minimal coherent recent activity aligned with bumetanide procurement specifically; state and local buyers appear to use this code for categorizing chemical and generic pharmaceutical commodity supply more broadly.